Characterization of LY344864 as a pharmacological tool to study 5-HT(1F) receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine

Life Sciences

Volumn 61, Issue 21, 1997, Pages 2117-2126

  Phebus, Lee A ^a   Johnson, Kirk W ^a   Zgombick, John M ^b   Gilbert, Pierre J ^a   Van Belle, Kristel ^a   Mancuso, Vincent ^a   Nelson, David L G ^a   Calligaro, David O ^a   Kiefer Jr , Anton D ^a   Branchek, Theresa A ^b   Flaugh, Michael E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

LY344864; Migraine; Neurogenic dural inflammation

Indexed keywords

N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; SEROTONIN 1 AGONIST; SEROTONIN 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN CORTEX; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; ELECTROSTIMULATION; EXTRAVASATION; IN VITRO STUDY; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIGRAINE; NONHUMAN; ORAL DRUG ADMINISTRATION; TRIGEMINUS GANGLION;

ANIMALS; BRAIN; CARBAZOLES; DISEASE MODELS, ANIMAL; DURA MATER; FLUOROBENZENES; HUMANS; INFLAMMATION; MALE; MIGRAINE DISORDERS; PROTEIN BINDING; RATS; RATS, INBRED F344; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN AGONISTS;

ANIMALIA;

EID: 0030721958     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00885-0     Document Type: Article

References (22)

1. N. ADHAM, H.T. KAO, L.E. SCHECTER, J. BARD, M. OLSEN, D. URQUHART, M. DURKIN, P.R. HARTIG, R.L. WEINSHANK, and T.A. BRANCHEK, Proc Natl Acad Sci U S A, 90 408-12 (1993).
2. N. ADHAM, L.A. BORDEN, L.E. SCHECHTER, E.L. GUSTAFSON, T.L. COCHRAN, P.J. VAYSSE, R.L. WEINSHANK, and T.A. BRANCHEK, Naunyn Schmiedebergs Arch Pharmacol, 348 566-75 (1993).
3. A.T. BRUINVELS, B. LANDWEHRMEYER, E.L. GUSTAFSON, M.M. DURKIN, G. MENGOD, T.A. BRANCHEK, D. HOYER and J.M. PALACIOS, Neuropharmacology 33 367-86 (1994).
4. C. WAEBER and M.A. MOSKOWITZ, Naunyn Schmiedebergs Arch Pharmacol, 352 263-75 (1995).
5. K.W. JOHNSON, J.M. SCHAUS, M.M. DURKIN, J.E. AUDIA, S.W. KALDOR, M.E. FLAUGH, N. ADHAM, J.M. ZGOMBICK, M.L. COHEN, T.A. BRANCHEK, and L.A. PHEBUS, Neuroreport 8 2237-40 (1997).
6. J.M. ZGOMBICK, R.L. WEINSHANK, M. MACCHI, L.E. SCHECHTER, T.A. BRANCHER, and P.R. HARTIG, Mol Pharmacol, 40 1036-42 (1991).
7. R.L. WEINSHANK, J.M. ZGOMBICK, M.J. MACCHI, T.A. BRANCHEK, and P.R. HARTIG, Proc Natl Acad Sci U S A, 89 3630-4 (1992).
8. D.B. WAINSCOTT, V.L. LUCAITES, J.D. KURSAR, M. BAEZ, and D.L. NELSON, J Pharmacol Exp Ther, 276 720-7 (1996).
9. E.L. GUSTAFSON, M.M. DURKIN, J.A. BARD, J. ZGOMBICK, and T.A. BRANCHEK, Br J Pharmacol, 117 657-66 (1996).
10. P. GREENGRASS and R. BREMNER, Eur J Pharmacol, 55 323-6 (1979).
11. C.L. BOYAJIAN and F.M. LESLIE, J Pharmacol Exp Ther, 241 1092-8 (1987).
12. D.E. BYLUND and S.H. SNYDER, Mol Pharmacol, 12 568-80 (1976).
13. C. BRAESTRUP and R.F. SQUIRES, Proc Natl Acad Sci U S A, 74 3805-9 (1977).
14. W. BILLARD, V. RUPERTO, G. CROSBY, L.C. IORIO, and A. BARNETT, Life Sci, 35 1885-93 (1984).
15. H. HALL, C. KOHLER, L. GAWELL, L. FARDE, and G. SEDVALL, Prog Neuropsychopharmacol Biol Psychiatry, 12 559-68 (1988).
16. M. WILLIAMS and E.A. RISLEY, J Neurochem, 32 713-8 (1979).
17. V.T. TRAN, R.S. CHANG, and S.H. SNYDER, Proc Natl Acad Sci U S A, 75 6290-4 (1978).
18. H.I. YAMAMURA and S.H. SNYDER, Proc Natl Acad Sci U S A, 71 1725-9 (1974).
19. L.A. PHEBUS, K.W. JOHNSON, P.W. STENGEL, K.L. LOBB, J.A. NIXON, and P.A. HIPSKIND, Life Sci, 60 1552-1561 (1997).
20. X.J. YU, C. CUTRER, M.A. MOSKOWITZ AND C. WAEBER, Neuropharmacology 36 83-91 (1997)
21. X.J. YU, C. WAEBER, N. CASTANON, K. SCEARCE, R. HEN, J.E. MACOR, J. CHAVEAU, and M.A. MOSKOWITZ, Mol Pharmacol, 49 761-5 (1996).
22. T. MATSUBARA, M.A. MOSKOWITZ, and B. BYUN, Br J Pharmacol, 104 3-4 (1991).